Prednisone Tapering Guidelines

General Principles

The European League Against Rheumatism recommends that the tapering schedule must be individualized based on initial dose, with higher doses requiring more gradual tapering 1
The American Society of Clinical Oncology suggests that the underlying condition being treated should be considered when determining the tapering schedule 2
For patients on chronic medium/high-dose therapy (>7.5 mg daily for >3 weeks), the European League Against Rheumatism recommends that adrenal insufficiency should be anticipated during tapering 3
The tapering schedule should be based on patient's response to treatment, according to the European League Against Rheumatism 3, 4

For medium-term therapy (3 weeks to 3 months), the European League Against Rheumatism recommends initial tapering to 10 mg/day within 4-8 weeks, then taper by 1 mg every 4 weeks 1, 4
For long-term therapy (more than 3 months), the American Association for the Study of Liver Diseases suggests initial reduction by small increments (e.g., 5 mg) until reaching 20 mg daily, then reduce by 5 mg weekly until reaching 10 mg daily 6
For disease-specific tapering, the European Society for Medical Oncology recommends tapering over 4-6 weeks for grade 1-2 pneumonitis, and over 4-6 weeks after clinical improvement for grade 3-4 pneumonitis 2, 7

Regular follow-up is essential, with monitoring every 4-8 weeks in the first year, and every 8-12 weeks in the second year, according to the European League Against Rheumatism 1, 4
The American Society of Clinical Oncology recommends monitoring for signs of disease relapse or flare, symptoms of adrenal insufficiency, and steroid withdrawal symptoms 1, 2, 3
Laboratory monitoring is recommended as appropriate for the underlying condition, according to the Society for Immunotherapy of Cancer 8
If disease relapses during tapering, the European League Against Rheumatism suggests increasing prednisone to the pre-relapse dose, then gradually decreasing within 4-8 weeks to the dose at which relapse occurred 1, 4

Patients on long-term therapy should be monitored for bone disease with baseline and annual bone mineral density testing, according to the American Association for the Study of Liver Diseases 6
Patients should be educated about the risk of adrenal insufficiency and how to manage it during acute illness or stress, according to the European League Against Rheumatism 3
Consider stress-dose steroids for patients who have been on prednisone >7.5 mg daily for more than 3 weeks, according to the European League Against Rheumatism 3